References
- Shannon M, Neuman MI. Yohimbine. Pediatr Emerg Care 2000; 16:49–50.
- Tam SW, Worcel M, Wyllie M. Yohimbine: a clinical review. Pharmacol Ther 2001; 91:215–243.
- Owen JA, Nakatsu SL, Fenemore J, Condra M, Surridge DHC, Morales A. The pharmacokinetics of Yohimbine in man. Eur J Clin Pharmacol 1987; 32:577–582.
- Hameedi FA, Woods SW, Rosen MI, Pearsall HR, Kosten TR. Dose dependent effects of Yohimbine on methadone maintained patients. Am J Drug Alcohol Abuse 1997; 23:327–333.
- Linden CH, Vellman WP, Rumack B. Yohimbine: a new street drug. Ann Emerg Med 1985; 14:1002–1004.
- Morales A, Surridge DH, Marshall PG, Fenemore J. Nonhormonal pharmacological treatment of organic impotence. J Urol 1982; 128:45–47.
- Tu NN, Haller CA, Kearney TE. Yohimbine adverse drug events [abstract]. Clin Toxicol 2007; 45:625.
- Grunewald KK, Bailey RS. Commercially marketed supplements for body building athletes. Sports Med 1993; 15:90–103.
- Halcomb SE, Parab S, Ravikumar PR, Hoffman RS, Nelson LS. Massive Yohimbine overdose associated with sodium channel blockade [abstract]. Clin Toxicol 2006; 44:731.
- Friesen K, Palatnick W, Tenenbein M. Benign course after massive Yohimbine ingestion. J Emerg Med 1993; 11:287–288.
- Varkey S. Overdose of Yohimbine. Br Med J 1992; 304:548.
- Vulto AG, de Smet PAGM. Drugs used in non-orthodox medicine. In: Dukes MNG, ed. Meyler's Side Effects of Drugs. 11th ed. Amsterdam: Elsevier; 1988:1024–1028.
- Le Corre P, Dollo G, Chevanne F, Le Verge R. Biopharmaceutics and metabolism of yohimbine in humans. Eur J Pharm Sci 1999; 9:79–84.
- Sturgill MG, Grasing KW, Rosen RC, Thomas TJ, Kulkarni GD, Trout JR, Maines M, Seibold JR. Yohimbine elimination in normal volunteers is characterized by both one- and two-compartment behavior. J Cardiovasc Pharmacol 1997; 29:697–703.